Aberrant expression of RSK4 in breast cancer and its role in the regulation of tumorigenicity

Int J Mol Med. 2017 Sep;40(3):883-890. doi: 10.3892/ijmm.2017.3069. Epub 2017 Jul 17.

Abstract

Breast cancer is the most frequently diagnosed cancer in both more and less economically developed countries and remains the leading cause of cancer-related death in women worldwide. In this study, to explore the expression and pathological role of RSK4 in breast cancer progression, we demonstrated that RSK4 expression was significantly decreased in breast cancer cells and tissues, and the overexpression of RSK4 in MDA‑MB‑231 cells inhibited cell migration and invasion. In a mouse model experiment, overexpression of RSK4 in mice further confirmed its critical role in regulating breast cancer tumorigenicity. The regulatory role of RSK4 in breast cancer development was mediated by AKT and extracellular signal‑regulated kinase (ERK) signaling pathways and the expression of RSK4 was altered by DNA methylation in promoter regions. These results provide important insight into the role of RSK4 in cancerogenesis and may help to improve the prevention, diagnosis and treatment of breast cancer.

MeSH terms

  • Aged
  • Animals
  • Breast Neoplasms / enzymology*
  • Breast Neoplasms / genetics
  • Breast Neoplasms / pathology
  • Female
  • Gene Expression Regulation, Enzymologic*
  • Gene Expression Regulation, Neoplastic*
  • Humans
  • MAP Kinase Signaling System*
  • MCF-7 Cells
  • Mice
  • Mice, Nude
  • Middle Aged
  • Proto-Oncogene Proteins c-akt / genetics
  • Proto-Oncogene Proteins c-akt / metabolism
  • Ribosomal Protein S6 Kinases, 90-kDa / biosynthesis*
  • Ribosomal Protein S6 Kinases, 90-kDa / genetics

Substances

  • Proto-Oncogene Proteins c-akt
  • RPS6KA6 protein, human
  • Ribosomal Protein S6 Kinases, 90-kDa